Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension

Conclusions: OS use over two years would result in lower total, drug, and hospitalization-related costs compared with OT, thus providing financial savings for payers.PMID:37800591 | DOI:10.1080/13696998.2023.2254160

Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Authors: John McConnell S Pinar Bilir Yifan Xu Yuen Tsang Sumeet Panjabi Source Type: research